Summer Flandermeyer
Family · Kansas City, MONPI 1063097616
Payments from drug & device makers
Across 84 payments — averaging $109.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MML US, Inc.$7K
- Saluda Medical Americas, Inc.$631
- Averitas Pharma Inc.$326
- Nevro Corp.$290
- Boston Scientific$186
- Nalu Medical, Inc.$173
- plus $660 from 10 others
What the payments were for
- Consulting fees$5,35058%
- Travel & lodging$91010%
- Food & beverage$2,94332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MML US, Inc. | 24 | $6,937 |
| Saluda Medical Americas, Inc. | 27 | $631 |
| Averitas Pharma Inc. | 6 | $326 |
| Nevro Corp. | 7 | $290 |
| Boston Scientific | 3 | $186 |
| Nalu Medical, Inc. | 2 | $173 |
| Globus Medical | 3 | $162 |
| Medtronic | 2 | $132 |
| Krystal Biotech Inc | 1 | $102 |
| Pfizer | 1 | $96 |
| Biotronik NRO, Inc. | 3 | $58 |
| Spinal Simplicity, LLC | 1 | $33 |
| GRT US Holding, Inc. | 1 | $32 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $15 |
| Electronic Waveform Lab, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ReActiv8$6,450
- Qutenza$236
- Intracept$150
- Nalu Neurostimulation System$147
- Evoke$118
- Senza$117
- INTELLIS ADAPTIVESTIM$106
- VYJUVEK$102
How this compares
$9,203 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 77 | $2,976 |
| Duloxetine Hcl | 100 | $2,453 |
| Tizanidine Hcl | 83 | $2,137 |
| Pregabalin | 143 | $2,091 |
| Gabapentin | 131 | $1,862 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $1,026 |
| Oxycodone Hcl | 27 | $779 |
| Morphine Sulfate ErMorphine Sulfate | 19 | $561 |
| Cyclobenzaprine Hcl | 17 | $174 |
| Tramadol Hcl | 15 | $120 |
| Meloxicam | 14 | $23 |
| Diazepam | 13 | $17 |
Paid to pharmacies, not to this prescriber.
Other family in Kansas City
- Shayla SandersKansas City$306K
- Oyinkan PennyKansas City$36K
- Goldie BenzKansas City$27K
- Lucy Carter ReardonKansas City$25K
- Lyla MastersKansas City$22K
- Donna McCurryKansas City$20K
- Mary Zahau LoehnerKansas City$20K
- Cherie NydeggerKansas City$17K
- Charity SlaytonKansas City$17K
- Samantha IrwinKansas City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.